- Home
- PPBT vs PAVM Comparison
PPBT vs PAVM Comparison
Compare PPBT & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- PAVM
- Stock Information
- Founded
- PPBT 2010
- PAVM 2014
- Country
- PPBT Israel
- PAVM United States
- Employees
- PPBT N/A
- PAVM N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- PPBT Health Care
- PAVM Health Care
- Exchange
- PPBT Nasdaq
- PAVM Nasdaq
- Market Cap
- PPBT 2.1M
- PAVM 8.0M
- IPO Year
- PPBT N/A
- PAVM 2016
- Fundamental
- Price
- PPBT $0.61
- PAVM $0.40
- Analyst Decision
- PPBT Strong Buy
- PAVM Strong Buy
- Analyst Count
- PPBT 1
- PAVM 1
- Target Price
- PPBT $33.00
- PAVM $19.00
- AVG Volume (30 Days)
- PPBT 2.9M
- PAVM 278.8K
- Earning Date
- PPBT 11-14-2025
- PAVM 11-12-2025
- Dividend Yield
- PPBT N/A
- PAVM N/A
- EPS Growth
- PPBT N/A
- PAVM N/A
- EPS
- PPBT N/A
- PAVM 0.83
- Revenue
- PPBT N/A
- PAVM $1,020,000.00
- Revenue This Year
- PPBT N/A
- PAVM N/A
- Revenue Next Year
- PPBT N/A
- PAVM $455.63
- P/E Ratio
- PPBT N/A
- PAVM $0.49
- Revenue Growth
- PPBT N/A
- PAVM N/A
- 52 Week Low
- PPBT $0.53
- PAVM $0.30
- 52 Week High
- PPBT $13.95
- PAVM $1.77
- Technical
- Relative Strength Index (RSI)
- PPBT 14.86
- PAVM 37.31
- Support Level
- PPBT $0.53
- PAVM $0.39
- Resistance Level
- PPBT $2.36
- PAVM $0.45
- Average True Range (ATR)
- PPBT 0.14
- PAVM 0.04
- MACD
- PPBT -0.05
- PAVM -0.00
- Stochastic Oscillator
- PPBT 3.95
- PAVM 10.34
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.